

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

DELAY IN DESPATCH OF CIRCULAR IN RELATION TO RENEWAL OF CONTINUING CONNECTED TRANSACTIONS

Reference is made to the announcement of Fusen Pharmaceutical Company Limited (the “**Company**”) dated 1 December 2023 (the “**Announcement**”) in relation to, among other things, the Renewed Master Chinese Medicine Purchase Agreement, the Renewed Master Packaging Materials Purchase Agreement, the Proposed Annual Caps and the transactions contemplated thereunder. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) details of the Renewed Master Chinese Medicine Purchase Agreement and the Renewed Master Packaging Materials Purchase Agreement, the Proposed Annual Caps and the transactions contemplated thereunder; (ii) the letter from the Independent Financial Adviser containing its advice to the Independent Board Committee and the Independent Shareholders on the Renewed Master Chinese Medicine Purchase Agreement and the Renewed Master Packaging Materials Purchase Agreement, the Proposed Annual Caps and the transactions contemplated thereunder; and (iii) the recommendation of the Independent Board Committee regarding the Renewed Master Chinese Medicine Purchase Agreement, the Renewed Master Packaging Materials Purchase Agreement, the Proposed Annual Caps and the transactions contemplated thereunder to the Independent Shareholders, is expected to be despatched to the Shareholders on or before 22 December 2023.

As additional time is required to prepare and finalise certain information to be contained in the Circular, the expected date of despatch of the Circular will be postponed to a date falling on or before 17 January 2024.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Changcheng
Chairman and Executive Director

Hong Kong, 2 January 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming (formerly known as Mr. Cao Dudu) as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.